Ocular Therapeutix (OCUL) Misses Q4 EPS by 4c

Ocular Therapeutix (NASDAQ: OCUL) reported Q4 EPS of ($0.29), $0.04 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $17.08 million versus the consensus estimate of $17.21 million.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.

You May Also Be Interested In

• HighPeak Energy mulls sale - Reuters
• FAA officials are preparing to launch an AI-powered air-traffic tool in one of the nation’s busiest corridors as soon as Monday - WSJ
• Huang and Altman to attend Trump-Xi state dinner - ABC